FDA
-
-
-
-
-
-
-
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
-
-
-
-
-
-
-
Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients
-
-
-
-
-
-
-
Pre-Open Stock Movers 01/20: (APM) (EVLO) (NFLX) Higher; (GEVO) (HSTO) (BLRX) Lower (more...)
-
-
-
-
-
-
-
Histogen Announces Filing an Investigational New Drug Application for HST-003
-
-
-
-
-
-
-
Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

